% | $
Quotes you view appear here for quick access.

Rigel Pharmaceuticals, Inc. Message Board

  • delphioracle2009 delphioracle2009 Jun 4, 2013 9:46 AM Flag

    RIGL one in a lifetime buy opportunity below $4/share ... Over 78% market cap in cash position

    As of first quarter end of March 31, 2013, RIGL had cash and cash equivalents of $272.5 million, and projects to end 2013 with over $200 million in cash and cash equivalent. With 87.14 million share the market cap at $4/share itself is only $348 million and current no-debt cash position of $272.5 million covers over 78% of market cap ...

    Compared to EXAS and VVUS that have one risky product each in their pipeline and have projected to make losses even in 2014, RIGL may be worth way more than 2x it current price ...

    RIGL CEO said James M. Gower, stated that "In the second quarter of 2013, we expect our partner AstraZeneca to report topline results from the two remaining Phase 3 studies of fostamatinib in rheumatoid arthritis, OSKIRA2 and OSKIRA3," . "Results from two other Phase 2 studies with R343 in allergic asthma and R333 in discoid lupus will follow later this year."

    RIGL seems to be well positioned for great rally in the near future ... jsut wait for the big money to move in and RIGL could shoot above $7/share ...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.64+0.03(+1.15%)Aug 29 4:00 PMEDT